Table 3. Common therapies for endometrial hyperplasia.
| Therapy type | Origin and formula | Routes of administration |
|---|---|---|
| Progestin therapy | ||
| Medroxy progesterone acetate | Steroidal progestin (C24H34O4) | Oral; intramuscular |
| Megestrol acetate | Steroidal progestin (C24H32O4) | Oral |
| Levonorgestrel | Synthetic progestogen (C21H28O2) | Implant; insert (extended-release); oral |
| Norethisterone acetate | Steroidal progestin (C22H28O3) | Oral |
| Megestrol acetate+metformin | - | Oral |
| Levonorgestrel-IUD+metformin | - | Oral or implant; insert (extended-release) |
| Other than progestin therapy | ||
| Danazol | Synthetic steroid ethisterone (C22H27NO2) | Oral |
| Genistein | Isoflavones (C15H10O5) | Oral |
| Metformin | Biguanide class (C4H11N5) | Oral |
| GnRH therapy | ||
| Histrelin | D-His(B21)6, Pro9-Net-GnRH (C66H86N18O12) | Subcutaneous implant |
| Nafarelin | D-Nal(2)6-GnRH (C66H83N17O13)s | Nasal spray |
IUD, intrauterine device; His, histidine; GnRH, gonadotropin-releasing hormone; NH2, amino group; Pro, proline.